IL2 and neoplasm: The first studies in murine tumor models revealed that administration of LAK cells alone did not lead to reduced growth of pulmonary metastases, while simultaneous administration of LAK cells and IL-2 resulted in a significant reduction in established pulmonary sarcoma metastases [73,74,75].